Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

Transplantation. 1999 Nov 27;68(10):1517-25. doi: 10.1097/00007890-199911270-00015.

Abstract

Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Epstein-Barr Virus Infections / etiology*
  • Epstein-Barr Virus Infections / physiopathology
  • Epstein-Barr Virus Infections / therapy
  • Herpesvirus 4, Human*
  • Humans
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / physiopathology
  • Lymphoproliferative Disorders / therapy
  • Organ Transplantation / adverse effects*
  • Postoperative Complications / virology*